Flag of the European Union EU Clinical Trials Register Help

Clinical trials for eudract

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    227 result(s) found for: eudract. Displaying page 6 of 12.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    EudraCT Number: 2012-004412-55 Sponsor Protocol Number: C.HO.SE. Start Date*: 2013-04-15
    Sponsor Name:AZIENDA PROVINCIALE PER I SERVIZI SANITARI DELLA PROVINCIA AUTONOMA DI TRENTO
    Full Title: Cabazitaxel in relapsed high-risk HOrmone-SEnsitive prostate cancer patients. A multicentric Randomized phase II study. C.HO.SE. Trial
    Medical condition: Relapsed high-risk hormone-sensitive prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-003810-42 Sponsor Protocol Number: Version2.0;18/12/2013 Start Date*: 2016-06-24
    Sponsor Name:University of Edinburgh (ACCORD) [...]
    1. University of Edinburgh (ACCORD)
    2. NHS Lothian (ACCORD)
    Full Title: A pragmatic group sequential placebo controlled randomised trial to determine the effectiveness of Glyceryl trinitrate for retained placenta (GOT-IT Trial)
    Medical condition: Retained placenta
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004868 10038757 Retained placenta LLT
    16.1 100000004865 10038350 Removal retained placenta LLT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-001417-16 Sponsor Protocol Number: SFA106484 Start Date*: 2007-01-03
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: A randomized, double-blind, double-dummy, parallel group study evaluating the safety of fluticasone propionate/salmeterol 100/50mcg HFA (2 inhalations of 50/25mcg) twice daily compared with flutica...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10003553 Asthma LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) LT (Completed) LV (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-001277-14 Sponsor Protocol Number: P01910 Start Date*: 2016-02-19
    Sponsor Name:Royal Papworth Hospital NHS Foundation Trust
    Full Title: A Randomised Mechanistic Study Comparing the Effects of Different Anti-platelet Combinations (Ticagrelor vs. Placebo/ Clopidogrel) with Aspirin in Patients presenting with STEMI Treated with Primar...
    Medical condition: Patients with ST segment elevation myocardial infarction
    Disease: Version SOC Term Classification Code Term Level
    21.1 10042613 - Surgical and medical procedures 10053460 Antiplatelet therapy PT
    20.0 10007541 - Cardiac disorders 10000891 Acute myocardial infarction PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2006-000937-37 Sponsor Protocol Number: PMR-EC-1205 Start Date*: 2006-08-29
    Sponsor Name:Astellas Pharma GmbH
    Full Title: A MULTICENTER, OPEN, SINGLE SEQUENCE CROSSOVER STUDY TO ASSESS THE SAFETY AND EFFICACY OF A TACROLIMUS MODIFIED RELEASE, FK506E (MR4), BASED IMMUNOSUPPRESSIVE REGIMEN IN STABLE KIDNEY TRANSPLANT PA...
    Medical condition: Stable, adult kidney transplant recipients (≥ 12 months post transplant) who are currently treated with Prograf.
    Disease: Version SOC Term Classification Code Term Level
    7.0 10024716 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) ES (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-000199-14 Sponsor Protocol Number: N01009 Start Date*: 2004-11-25
    Sponsor Name:UCB Pharma S.A. [...]
    1. UCB Pharma S.A.
    2. UCB Pharma Inc.
    Full Title: A double-blind, randomized, multicenter, placebo-controlled, in-patients maximum 34 day study of levetiracetam oral solution (20-50 mg/kg/day) as adjunctive treatment of refractory partial onset se...
    Medical condition: Epilepsy - Refractory Partial Onset Seizures
    Disease: Version SOC Term Classification Code Term Level
    7.0 10061334 LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed) GB (Completed) BE (Completed) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2022-002885-34 Sponsor Protocol Number: CHIP-AML22/Master Start Date*: 2023-03-17
    Sponsor Name:Princess Máxima Center
    Full Title: CHIP-AML22 Master protocol: An open label complex clinical trial in newly diagnosed pediatric de novo AML patients – a study by the NOPHO-DB-SHIP consortium
    Medical condition: Acute Myeloid Leukemia
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-003469-18 Sponsor Protocol Number: EU820UPV01 Start Date*: 2005-11-07
    Sponsor Name:Toray Industries, Inc.
    Full Title: CLINICAL TRIAL NO: EU820UPV01 A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF TRK-820 IN HEMODIALYSIS PATIENTS WITH UREMIC PRURITUS EudraCT No: 2005-003469-18 Short Title: TRK-820 UP 5...
    Medical condition: Patients on hemodialysis three times a week suffering from Uremic Pruritus (UP), uncontrolled by current medication(s) and/or treatment(s), will be enrolled.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) BE (Completed) CZ (Completed) IT (Completed) SK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-003377-97 Sponsor Protocol Number: KLLVACC-2018 Start Date*: 2018-12-18
    Sponsor Name:Swedish CLL-group
    Full Title: Long term effect on immune response after pneumococcal vaccination in patients with chronic lymphocytic leukemia and evaluation of the effect of revaccination.
    Medical condition: The aim of the study is to evaluate pneumococcal vaccination strategy with PPSV23 and PCV13 in patients with chronic lymphocytic leukemia (CLL) initially randomized in a clinical study.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001632-10 Sponsor Protocol Number: SARS-CoV-2CP-HD-001 Start Date*: 2020-05-04
    Sponsor Name:Ruprecht-Karls-Universität Heidelberg, Medical Faculty, University Hospital Heidelberg -
    Full Title: A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 D...
    Medical condition: Coronavirus disease 2019 (COVID-19) / SARS-CoV-2 Disease
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10084268 COVID-19 PT
    23.1 10042613 - Surgical and medical procedures 10084460 COVID-19 treatment PT
    23.0 10021881 - Infections and infestations 10084270 SARS-CoV-2 acute respiratory disease LLT
    23.0 10021881 - Infections and infestations 10084272 SARS-CoV-2 infection LLT
    23.1 100000004848 10084439 SARS-CoV-2 serology test positive LLT
    21.1 10042613 - Surgical and medical procedures 10054540 Passive immunization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-002348-57 Sponsor Protocol Number: 2021-002348-57 Start Date*: 2021-05-30
    Sponsor Name:Medical University of Vienna
    Full Title: A Randomized, Parallel Group, Single-Blind, Phase 2 Study to Evaluate the immune response of two classes of SARS-Cov-2 Vaccines employed as Third Vaccination in Patients under current Rituximab The...
    Medical condition: Vaccination against SARS-CoV-2 in patients with rituximab therapy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2021-002693-10 Sponsor Protocol Number: VAC3_SARS-CoV2_seroconversion_study Start Date*: 2021-07-15
    Sponsor Name:Medical University of Vienna, Department for Internal Medicine III, Division of Rheumatology
    Full Title: A Phase II Study to Evaluate Safety and Efficacy to a Third Vaccination in Immunocompromised Patients with Inadequate Humoral Response after Primary mRNA SARS-CoV-2 (Covid-19) Vaccination
    Medical condition: Vaccination against SARS-CoV-2 in patients with immunosuppressive therapy or immunodeficiencies
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004617-12 Sponsor Protocol Number: INTEGRATE_IIb Start Date*: 2023-07-04
    Sponsor Name:Australasian Gastro-Intestinal Trials Group (AGITG)
    Full Title: INTEGRATE IIb - A Randomised Phase III Open Label Study of regorafenib + nivolumab vs standard chemotherapy in Refractory Advanced Gastro-Oesophageal Cancer (AGOC)
    Medical condition: refractory, advanced gastro-oesophageal cancer
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062878 Gastrooesophageal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-004382-39 Sponsor Protocol Number: KZR-616-003E Start Date*: 2022-02-15
    Sponsor Name:Kezar Life Sciences, Inc.
    Full Title: An Open-label Extension to the Phase 2 Randomized, Double-blind, Placebo-controlled, Crossover Multicenter Study to Evaluate the Safety and Efficacy of KZR-616 in the Treatment of Patients with Act...
    Medical condition: Autoimmune Disorders Polymyositis and Dermatomyositis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10003816 Autoimmune disorders HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2017-003916-37 Sponsor Protocol Number: 08448 Start Date*: 2018-04-13
    Sponsor Name:Newcastle Upon Tyne Hospitals NHS Foundation Trust
    Full Title: Multicentre, open label, prospective, single arm study of the safety and impact of eculizumab withdrawal in patients with atypical haemolytic uraemic syndrome
    Medical condition: Atypical Haemolytic Uraemic Syndrome (aHUS)
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2005-005745-18 Sponsor Protocol Number: EUDRACT 2005-005745-18 Start Date*: 2007-10-10
    Sponsor Name:Emma Children's Hospital-AMC
    Full Title: Levamisole treatment for children with steroid sensitive nephrotic syndrome. A multi-centre, double-blind, placebo-controlled, randomised trial.
    Medical condition: Steroid Sensitive Nephrotic Syndrome (SSNS)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029172 Nephrotic syndrome with unspecified pathological lesion in kidney LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-006176-39 Sponsor Protocol Number: GOIM21001 Start Date*: 2012-07-12
    Sponsor Name:GOIM GRUPPO ONCOLOGICO MERIDIONALE
    Full Title: Paclitaxel + Bevacizumab versus doxorubicina liposomiale non pegilata (Myocet), cyclophosfamide e Bevacizumab as the first line treatment in HER-2 negative metastatic breast cancer. Multicenter ran...
    Medical condition: metastatic breast cancer HER2 negative
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-000393-35 Sponsor Protocol Number: GOIM21002 Start Date*: 2012-02-01
    Sponsor Name:GOIM GRUPPO ONCOLOGICO MERIDIONALE
    Full Title: a multicenter phase II trial of nab-paclitaxel and capecitabine as first line treatment in Her-2 negative metastatic breast cancer (MBC)
    Medical condition: metastatic breast cancer (MBC) Her-2 negative as first line treatment
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001325-28 Sponsor Protocol Number: GOIM21003 Start Date*: 2012-07-17
    Sponsor Name:GOIM GRUPPO ONCOLOGICO MERIDIONALE
    Full Title: non-Pegylated liposomal doxrubicina (Myocet) + cyclophosphamide versus non pegylated liposomal doxorubicin (Myocet) + metronomic cyclophosphamide in metastatic breast cancer-a multicenter randomize...
    Medical condition: patients wiyh metastatic breast cancer her2 negative first line treatment
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001447-12 Sponsor Protocol Number: 331-10-234 Start Date*: 2019-01-11
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: A Multicenter, Randomized, Double-blind, Placebo- and Active controlled Trial to Evaluate the Efficacy of Brexpiprazole Monotherapy for the Treatment in Adolescents (13-17 years old) With Schizophr...
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10039636 Schizophrenia simple LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) ES (Ongoing) PL (Completed) BG (Prematurely Ended) FR (Completed) IT (Completed) RO (Ongoing)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Jun 26 13:10:37 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA